![(R)-2-[(2H-1,3-BENZODIOXOL-5-YL)METHYL]PYRROLIDINE AND PROCESSES FOR PREPARATION, COMPOSITIONS AND USES THEREOF](/docs/US/2024-10-03/US20240325338A1/abs.jpg.600x600.jpg)
- 专利标题： (R)-2-[(2H-1,3-BENZODIOXOL-5-YL)METHYL]PYRROLIDINE AND PROCESSES FOR PREPARATION, COMPOSITIONS AND USES THEREOF
-
申请号： US18739924申请日： 2024-06-11
-
公开(公告)号： US20240325338A1公开(公告)日： 2024-10-03
- 发明人: Harpreet Kaur , Tao Xin
- 申请人： PharmAla Biotech Inc.
- 申请人地址： CA Vancouver
- 专利权人： PharmAla Biotech Inc.
- 当前专利权人： PharmAla Biotech Inc.
- 当前专利权人地址： CA Vancouver
- 分案原申请号： US18380423 2023.10.16
- 主分类号： A61K31/335
- IPC分类号： A61K31/335 ; A61K31/4025 ; A61P25/00 ; C07D405/10
![(R)-2-[(2H-1,3-BENZODIOXOL-5-YL)METHYL]PYRROLIDINE AND PROCESSES FOR PREPARATION, COMPOSITIONS AND USES THEREOF](/abs-image/US/2024/10/03/US20240325338A1/abs.jpg.150x150.jpg)
摘要：
The present application includes an enantiomerically pure compound of Formula (R)-I or a salt and/or solvate thereof
Also included are compositions of the enantiomerically pure compound of Formula (R)-I as well as methods of using the compound of Formula (R)-I or composition thereof for treating, for example, disease, disorder or condition that benefits from psychotherapy.
The present application also includes a composition comprising a non-racemic mixture a compound of Formula (R)-I, or a salt and/or solvate thereof, and (S)-I, or a salt and/or solvate thereof:
wherein (R)-I, or a salt and/or solvate thereof, is present in the composition in a greater amount by enantiomeric equivalents, relative to (S)-I, or a salt and/or solvate thereof and uses thereof.
Further included are process preparing a compound of Formula (R)-I or (S)-I.
Also included are compositions of the enantiomerically pure compound of Formula (R)-I as well as methods of using the compound of Formula (R)-I or composition thereof for treating, for example, disease, disorder or condition that benefits from psychotherapy.
The present application also includes a composition comprising a non-racemic mixture a compound of Formula (R)-I, or a salt and/or solvate thereof, and (S)-I, or a salt and/or solvate thereof:
wherein (R)-I, or a salt and/or solvate thereof, is present in the composition in a greater amount by enantiomeric equivalents, relative to (S)-I, or a salt and/or solvate thereof and uses thereof.
Further included are process preparing a compound of Formula (R)-I or (S)-I.
信息查询
